Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.61 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.53 |
| ▸ | NCOR1 | O75376 | 6/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094176 | 0.94 | CAMKK2 (0.58) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5094681 | 0.88 | MAPK8 (0.54) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5100599 | 0.83 | CAMKK2 (0.54) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5092037 | 0.83 | CAMKK2 (0.58) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5099819 | 0.82 | HDAC1 (0.56) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5091711 | 0.82 | MAPK8 (0.55) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL27576350 | 0.81 | CAMKK2 (0.55) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL29784912 | 0.81 | HDAC3 (0.77) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5100273 | 0.81 | CAMK2D (0.55) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 | |
| SCHEMBL5094438 | 0.81 | CAMKK2 (0.54) | CAMKK2MAPK8GSK3BPIK3CGHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100506801-C | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| CN-1592743-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2005-03-09 | — | — | CN | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CAMKK2 692/4885MAPK8 878/4885GSK3B 1/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CAMKK2 707/4885MAPK8 849/4885GSK3B 1/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CAMKK2 707/4885MAPK8 849/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.